Date:			1/18/2023			
You	r Name:		Karen Louise Thomsen	Karen Louise Thomsen		
Manuscript Title:			Role of Ammonia in NAFLD: An Unusual Su	Role of Ammonia in NAFLD: An Unusual Suspect		
Manuscript Number (if known):			: _JHEPR-D-22-00687			
con affe indi The epic that	tent of your manusci ected by the content cate a bias. If you ar author's relationship demiology of hyperte t medication is not m	ript. "For the control of the contro	nanuscript. Disclosure represents a commitme ubt about whether to list a relationship/activity rities/interests should be defined broadly. For eyou should declare all relationships with manufed in the manuscript.  port for the work reported in this manuscript w	ot-for-profit third parties whose interests may be nt to transparency and does not necessarily //interest, it is preferable that you do so.  example, if your manuscript pertains to the facturers of antihypertensive medication, even if		
		relati	all entities with whom you have this onship or indicate none (add rows as d)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
			Time frame: Since the initial planning	of the work		
present manuscript (e.g., Novo N		Nov	None  Nordisk Foundation grant. Clinical Emerging stigator 2019 (NFF19OC0055039)	CBCR this talls key to add with thorsel down		
			Time frame: past 36 months			
Grants or contracts from any entity (if not indicated in item #1 above).			None			
3	Royalties or licenses		None			
4	Consulting fees	$\boxtimes$	None			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None	
11	Stock or stock options	⊠ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None	
13	Other financial or non-financial interests	⊠ None	

Date:			1/17/2023			
You	ur Name:		Peter Lykke Eriksen			
Manuscript Title:			Role of Ammonia in NAFLD: An Unusual Suspect			
Manuscript Number (if known):			JHEPR-D-22-00687			
cor affe ind The epi tha	ntent of your manuscrected by the content of icate a bias. If you are author's relationship demiology of hypertent medication is not me	ipt. "Rela of the man e in doubt os/activitiension, you entioned	ated" means any relation with for-profit or no nuscript. Disclosure represents a commitme t about whether to list a relationship/activity es/interests should be defined broadly. For a u should declare all relationships with manual in the manuscript.	•		
		relations	entities with whom you have this hip or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)		
			Time frame: Since the initial planning	of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	⊠ No	one	Clark they to a fitte deliterary makes		
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	⊠ No	Time frame: past 36 month			
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for					

 $\times$ 

None

Consulting fees

4

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	None     Non	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None	
11	Stock or stock options	⊠ None	

		e all entities with whom you have this ionship or indicate none (add rows as ed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	

Date:			1/19/2023			
Υοι	ır Name:		Annarein J.C. Kerbert			
Manuscript Title:			Role of Ammonia in NAFLD: An Unusual Suspect			
Manuscript Number (if known):			JHEPR-D-22-00687			
con affe indi The epic tha	tent of your manusc ected by the content icate a bias. If you an author's relationshi demiology of hyperte t medication is not m	ript. "Rela of the ma re in doub ps/activiti ension, yo nentioned t all suppo	ated" means any relation with for-profit or n nuscript. Disclosure represents a commitme t about whether to list a relationship/activity es/interests should be defined broadly. For u should declare all relationships with manu- in the manuscript.	//interest, it is preferable that you do so.		
relations			l entities with whom you have this ship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)		
			Time frame: Since the initial planning	of the work		
1 All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.		⊠ No	one	key and state the key		
			Time frame: past 36 month	s		
Grants or		⊠ N	one			
3	Royalties or licenses	⊠ Ne	one			

 $\boxtimes$ 

None

Consulting fees

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	⊠ None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None	
11	Stock or stock options	⊠ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None     ■	
13	Other financial or non-financial interests	⊠ None	

Date:			1/18/2023			
Υοι	ır Name:		Francesco De Chiara			
Manuscript Title:			Role of Ammonia in NAFLD: An Unusual Suspect			
Ma	nuscript Number (if k	nown):	JHEPR-D-22-00687			
content of your manuscript. "Rela affected by the content of the man indicate a bias. If you are in doubt The author's relationships/activitie epidemiology of hypertension, you that medication is not mentioned			ated" means any relation with for-profit or nonuscript. Disclosure represents a commitment about whether to list a relationship/activity es/interests should be defined broadly. For a should declare all relationships with manufain the manuscript.	/interest, it is preferable that you do so.		
			entities with whom you have this thip or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)		
			Time frame: Since the initial planning	of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	⊠ No	Time frame: Since the initial planning	of the work		
1	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	⊠ No		maniferal key manifab plant now		
2	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for		one	maniferal key manifab plant now		
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.  Grants or contracts from any entity (if not indicated in item	⊠ No	Time frame: past 36 month	maniferal key manifab mana naw		

 $\times$ 

None

4

Consulting fees

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	⊠ None	
6	Payment for expert testimony	⊠ None	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None	
11	Stock or stock options	⊠ None	

			with whom you have this licate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None		
13	Other financial or non-financial interests	⊠ None		
Plea	se place an "X" nex	to the following st	atement to indicate your agre	ement:

Date: Your Name:  Manuscript Title:			1/19/2023		
			Prof Rajiv Jalan  Role of ammonia in NAFLD: An unusual suspect		
Ma	nuscript Number (if	known):	JHEPR-D-22-00687		
con affe indi The epic that	tent of your manusci ected by the content cate a bias. If you ar author's relationship demiology of hyperte t medication is not m	ript. "Rela of the man re in doubt ps/activition ension, you nentioned	ated" means any relation with for-profit or nonuscript. Disclosure represents a commitment about whether to list a relationship/activity es/interests should be defined broadly. For a should declare all relationships with manufain the manuscript.	/interest, it is preferable that you do so.	
			entities with whom you have this thip or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		35.0	Time frame: Since the initial planning	of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Europea Horizon	an Union H2020 grant. European Union's 1 2020 research and innovation program 1 grant agreement number 733057	Chek the tablecy to stid additional rows	
ď			Time frame: past 36 month	s	
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ No	one		
3	Royalties or licenses	Founde	one r of Yaqrit Ltd. a UCL spinout, which holds or DIALIVE	No payments made yet	
4	Consulting fees		lone		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Takeda	Institution		
		Grifols	Institution		
		Surrozen	Institution		
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None			
		Grifols, Grant adjudication committee; Speaking	Institution		
6	Payment for expert testimony	⊠ None			
_		None			
7	Support for attending meetings and/or travel	⊠ None			
8	Patents planned, issued or	□ None			
	pending	Patents licensed by my University to Mallinckrodt, Yaqrit and Hepyx.	No payments made		
9	Participation on a Data Safety	⊠ None			
	Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role in	None			
	other board,	Scientific Director, EF CLIF			
	society,				
	committee or advocacy group, paid or unpaid				
11	Stock or stock options	□ None			
		Founder of Yaqrit Ltd., Hepyx Ltd., Cyberliver Ltd.			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None	
13	Other financial or non-financial interests	⊠ None	

# Jan. 18, 2023ICMJE DISCLOSURE FORM

1/18/2023

Date:

Υοι	ır Name:		Hendrik vilstrup		
Manuscript Title:			Role of Ammonia in NAFLD: An Unusual Suspect		
Ma	nuscript Number (if	known	: _JHEPR-D-22-00687		
con affe indi The epic tha	etent of your manusci ected by the content icate a bias. If you ar author's relationship demiology of hyperte t medication is not m	ript. "For of the re in do ps/activension, nention	elated" means any relation with for-profit or no nanuscript. Disclosure represents a commitme ubt about whether to list a relationship/activity ities/interests should be defined broadly. For e you should declare all relationships with manufed in the manuscript.	/interest, it is preferable that you do so. example, if your manuscript pertains to the acturers of antihypertensive medication, even if	
			all entities with whom you have this onship or indicate none (add rows as d)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.		None	vikil the talker to sall editional over	
			Time frame: past 36 month		
2	Grants or contracts from any entity (if not indicated in item #1 above).		None		
3	Royalties or licenses		None		
4	Consulting fees	$\boxtimes$	None		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None     Non	
7	Support for attending meetings and/or travel	⊠ None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None     Non	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None	
13	Other financial or non-financial interests	⊠ None	